Aged garlic extract may be safe for patients on warfarin therapy

Journal of Nutrition

Volumn 136, Issue 3, 2006, Pages

  Macan, Henry ^a   Uykimpang, Rolando ^a   Alconcel, Marcionila ^a   Takasu, Junichiro ^a   Razon, Rafael ^a   Amagase, Harunobu ^b,c   Niihara, Yutaka ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Wakunaga of America Co   (United States)

^c Wakunaga of America Co Ltd   (United States)

Author keywords

Aged garlic extract; Oral anticoagulation therapy; S allylcysteine; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; GARLIC EXTRACT; PLACEBO; WARFARIN;

ADULT; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMMON COLD SYMPTOM; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOEMBOLISM;

ALLIUM SATIVUM;

EID: 33644847423     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/136.3.793s     Document Type: Conference Paper

References (27)

1. Sumiyoshi H. New pharmaceutical activities of garlic and its constituents. Nippon Yakurigaku Zasshi. 1997;110: Suppl 1:93P-7P.
2. Rivlin RS. Historical perspective on the use of garlic. J Nutr. 2001;131: 951S-4S.
3. Steiner M, Khan AH, Holbert D, Lin RI. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr. 1996;64:866-70.
4. Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol. 1998;31:904-8.
5. Matsuura H. Saponins in garlic as modifiers of the risk of cardiovascular disease. J Nutr. 2001;131:1000S-5S.
6. Steiner M, Li W. Aged garlic extract, a modulator of cardiovascular risk factors: a dose-.nding study on the effects of AGE on platelet functions. J Nutr. 2001;131:980S-4S.
7. Rahman K. Historical perspective on garlic and cardiovascular disease. J Nutr. 2001;131:977S-9S.
8. Lamm DL, Riggs DR. Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. J Nutr. 2001;131:1067S-70S.
9. Borek C. Antioxidant health effects of aged garlic extract. J Nutr. 2001; 131:1010S-5S.
10. Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. J Nutr. 2000;130:2662-5.
11. Ohnishi ST, Ohnishi T. In vitro effects of aged garlic extract and other nutritional supplements on sickle erythrocytes. J Nutr. 2001;131:1085S-92S.
12. Moriguchi T, Takasugi N, Itakura Y. The effects of aged garlic extract on lipid peroxidation and the deformability of erythrocytes. J Nutr. 2001;131:1016S-9S.
13. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother. 2000;34:1478-82.
14. Rosenfeld V, Sisca T, Callahan A, Crain J. Double-blind, randomized, placebo-controlled trial of aged garlic extract in patients stabilized on warfarin therapy. American Society of Health-System Pharmacists; 2000 December 3-7; Las Vegas, Nevada.
15. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57(13):1221-7; quiz 1228-30.
16. Bloch A, Ben-Chetrit E, Muszkat M, Caraco Y. Pharmacotherapy. 2002;22:97-101.
17. Chatap G, Chiabi P, Giraud K, Sadji F, Vincent JP. Oral anticoagulation in older patients. Establishment and validation of a new posologic warfarin regimen. Presse Med. 2001;30:475-80.
18. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost. 1995;74:1055-8.
19. Ciaccheri M, Castelli G, Nannini M, Santoro G, Troiani V, Dolara A. Oral anticoagulant therapy in dilated cardiomyopathy. Warfarin treatment results in subgroups of patients at risk of embolic complications. G Ital Cardiol. 1995;25:689-94.
20. Chikada M, Yagyu K, Kotsuka Y, Furuse A. Anticoagulation therapy after mechanical prosthetic heart valve replacement with special reference to international normalized ration (INR). Kyobu Geka. 1994;47:895-8.
21. Gottlieb L, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154:1945-53.
22. Uetsuka Y, Katsuki T, Aosaki M, Iwade K, Hashimoto A, Koyanagi H, Saito M, Yaginuma Y, Hosoda S. International normalized ration (INR) for optimal anticoagulant therapy. Kokyu Tu Junkan. 1993;41:885-90.
23. Moriyasu H, Yasaka M, Oita J, Yamaguchi T. Warfarin therapy for secondary prevention of cardioembolic stroke with nonvalvular atrial fibrillation - a retrospective study. Rinsho Shinkeigaku. 1993;33:850-5.
24. Sivathasan C, Chia FK. Thromboemobolism and problems of anticoagulation after prosthetic valve replacement. Ann Acad Med Singapore. 1988;17:434-7.
25. Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Outpatient management of anticoagulation. Compr Ther. 1975;1:65-9.
26. Petry JJ. Garlic and postoperative bleeding. Plast Reconstr Surg. 1995;96:483-4.
27. Palareti G, Leali N, Cocheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, et al. Bleeding complications of oral anticoagulant treatment: an inception: cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet. 1996;348:423-8.